Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onasemnogene abeparvovec-xioi (Zolgensma) in SMA Type 1
NCT03461289Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 4
01
Overview
A Phase 3 trial of onasemnogene abeparvovec in spinal muscular atrophy type 1, sponsored by Novartis. Started Aug 2018; status: completed.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy type 1
Beyond the preview
Go deeper on NCT03461289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461289.